SEARCH:   Advanced

Blood, 1 March 2004, Vol. 103, No. 5, pp. 1846-1854. Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-08-2836. This Article Full Text (PDF) All Versions of this Article: 2003-08-2836v1 103/5/1846    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mone, A. Articles by Byrd, J. C Search for Related Content PubMed PubMed Citation Articles by Mone, A. Articles by Byrd, J. C Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted August 25, 2003 Accepted October 16, 2003 Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Andrew Mone, Peng Huang, Helene Pelicano, Carolyn M Cheney, Jennifer M Green, J Yun Tso, Amy J Johnson, Sara Jefferson, Thomas S Lin, and John C Byrd* Department of Medicine, The Ohio State University, Columbus, OH, USA Department of Molecular Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA Protein Design Labs Inc, Fremont, CA, USA * Corresponding author; email: byrd-3{at}medctr.osu.edu. The 1D10 antigen is the target for Hu1D10 (apolizumab), a humanized HLA-DR b-chain specific antibody that is currently in clinical trials for hematologic malignancies. We demonstrate that Hu1D10 induces caspase independent apoptosis following secondary cross-linking in primary CLL cells. Generation of reactive oxygen species and signal transduction, as evidenced by phosphorylation of Syk and AKT, was noted. The source of the Hu1D10 induced reactive oxygen species was examined using the Raji lymphoblastic cell line with engineered defects in the mitochondrial respiratory chain. Hu1D10 treatment of clones with deficient mitochondrial respiration produced reactive oxygen species suggesting a cytoplasmic source. Administration of reactive oxygen species scavengers to primary CLL cells prior to Hu1D10 treatment diminished AKT activation. Treatment with Hu1D10 and the PI3 kinase inhibitor LY294002 demonstrated in vitro synergy with enhanced apoptosis. In conjunction with an ongoing clinical trial, blood samples were collected following intravenous infusion of Hu1D10 and analyzed for phosphorylation of AKT. Two of three patient samples showed a sustained increase in AKT phosphorylation following Hu1D10 administration. These data suggest Hu1D10 ligation in CLL cells induces death and survival signals for which combination therapies may be designed to greatly enhance efficiency of both Hu1D10 and other class II antibodies in development. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Monoclonal antibodies in the treatment of chronic lymphocytic leukemia: if only it were simple Emili Montserrat Blood 2004 103: 1567-1568. [Full Text] [PDF] This article has been cited by other articles: R. Lapalombella, B. Yu, G. Triantafillou, Q. Liu, J. P. Butchar, G. Lozanski, A. Ramanunni, L. L. Smith, W. Blum, L. Andritsos, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells Blood, December 15, 2008; 112(13): 5180 - 5189. [Abstract] [Full Text] [PDF] G. S. Di Marco, M. Hausberg, U. Hillebrand, P. Rustemeyer, W. Wittkowski, D. Lang, and H. Pavenstadt Increased inorganic phosphate induces human endothelial cell apoptosis in vitro Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1381 - F1387. [Abstract] [Full Text] [PDF] X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood, October 1, 2007; 110(7): 2569 - 2577. [Abstract] [Full Text] [PDF] P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s. [Abstract] [Full Text] [PDF] C. Bello and E. M. Sotomayor Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond Hematology, January 1, 2007; 2007(1): 233 - 242. [Abstract] [Full Text] [PDF] R. Stein, Z. Qu, S. Chen, D. Solis, H. J. Hansen, and D. M. Goldenberg Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab Blood, October 15, 2006; 108(8): 2736 - 2744. [Abstract] [Full Text] [PDF] J. Ramos, M. Sirisawad, R. Miller, and L. Naumovski Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation Mol. Cancer Ther., May 1, 2006; 5(5): 1176 - 1182. [Abstract] [Full Text] [PDF] C. Carlo-Stella, M. Di Nicola, M. C. Turco, L. Cleris, C. Lavazza, P. Longoni, M. Milanesi, M. Magni, M. Ammirante, A. Leone, et al. The Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice Cancer Res., February 1, 2006; 66(3): 1799 - 1808. [Abstract] [Full Text] [PDF] A. Mone, S. Puhalla, S. Whitman, R. A. Baiocchi, J. Cruz, T. Vukosavljevic, A. Banks, C. F. Eisenbeis, J. C. Byrd, M. A. Caligiuri, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia Blood, November 15, 2005; 106(10): 3380 - 3382. [Abstract] [Full Text] [PDF] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] T. D. Shanafelt, Y. K. Lee, N. D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, and N. E. Kay Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine Blood, March 1, 2005; 105(5): 2099 - 2106. [Abstract] [Full Text] [PDF] A. M. Evens, P. Lecane, D. Magda, S. Prachand, S. Singhal, J. Nelson, R. A. Miller, R. B. Gartenhaus, and L. I. Gordon Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells Blood, February 1, 2005; 105(3): 1265 - 1273. [Abstract] [Full Text] [PDF] R.-h. Xu, H. Pelicano, Y. Zhou, J. S. Carew, L. Feng, K. N. Bhalla, M. J. Keating, and P. Huang Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia Cancer Res., January 15, 2005; 65(2): 613 - 621. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020